GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (STU:TA50) » Definitions » EV-to-EBIT

Circio Holding ASA (STU:TA50) EV-to-EBIT : 0.92 (As of May. 27, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Circio Holding ASA EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Circio Holding ASA's Enterprise Value is €4.62 Mil. Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €5.01 Mil. Therefore, Circio Holding ASA's EV-to-EBIT for today is 0.92.

The historical rank and industry rank for Circio Holding ASA's EV-to-EBIT or its related term are showing as below:

STU:TA50' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.4   Med: -2.46   Max: 0.95
Current: 0.92

During the past 13 years, the highest EV-to-EBIT of Circio Holding ASA was 0.95. The lowest was -12.40. And the median was -2.46.

STU:TA50's EV-to-EBIT is ranked better than
66.39% of 476 companies
in the Biotechnology industry
Industry Median: 8.245 vs STU:TA50: 0.92

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Circio Holding ASA's Enterprise Value for the quarter that ended in Dec. 2024 was €2.85 Mil. Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €5.01 Mil. Circio Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 176.19%.


Circio Holding ASA EV-to-EBIT Historical Data

The historical data trend for Circio Holding ASA's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA EV-to-EBIT Chart

Circio Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.50 -3.10 -0.42 -1.30 0.85

Circio Holding ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.42 -1.30 - 0.85

Competitive Comparison of Circio Holding ASA's EV-to-EBIT

For the Biotechnology subindustry, Circio Holding ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Circio Holding ASA's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Circio Holding ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Circio Holding ASA's EV-to-EBIT falls into.


;
;

Circio Holding ASA EV-to-EBIT Calculation

Circio Holding ASA's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.620/5.013
=0.92

Circio Holding ASA's current Enterprise Value is €4.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €5.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA  (STU:TA50) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Circio Holding ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=5.013/2.8452816
=176.19 %

Circio Holding ASA's Enterprise Value for the quarter that ended in Dec. 2024 was €2.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Circio Holding ASA's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €5.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Circio Holding ASA EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Circio Holding ASA Business Description

Traded in Other Exchanges
Address
Saint Olavs plass, Pb. 6887, Oslo, NOR, 0130
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients. The company's pipeline candidate includes circVec and Mutant KRAS.

Circio Holding ASA Headlines

No Headlines